SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
SGLT2 inhibitors tied to lower risk of dementia, Parkinson’s disease, suggests study
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson’s disease, according to a study published in the September 18, 2024, online issue of Neurology®,
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, lower blood sugar by prompting the kidneys to filter sugar out of the bloodstream and excrete it in urine,
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new study.
GlobalData on MSN20d
Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis
A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...
Endocrinology Advisor4d
SGLT2 Inhibitors Cut Kidney Risks Across CKD, Heart Failure, Diabetes Spectrum
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
Medscape8d
SGLT2 Inhibitor Reduces Risk for Neurodegenerative Diseases in T2D
"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...
Daily10d
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...
The American Journal of Managed Care25d
SGLT2 Inhibitors, GLP-1 Agonists Similarly Reduce Dementia Risk for Patients With Diabetes
New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. New research ...
Medscape11d
Do SGLT2 Inhibitors Benefit Everyone With T2D and CKD?
New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...
Medical Xpress19d
SGLT2 inhibitor empagliflozin is shown to be safe and effective for treating patients who have suffered a heart attack
Citation: SGLT2 inhibitor empagliflozin is shown to be safe and effective for treating patients who have suffered a heart attack (2024, September 2) retrieved 20 September 2024 from https ...
Knowridge12d
This common diabetes drug may cause dangerous infection, study finds
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a newer class of drugs used to manage diabetes, have recently been linked ...
Renal & Urology News10d
SGLT2 Inhibitors Cut Kidney Risks Across CKD, Heart Failure, Diabetes Spectrum
SGLT2 inhibitors reduce the risk for adverse kidney outcomes across most high-risk populations with CKD, heart failure, and/or type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (SGLT2i ...